AKBA Akebia Therapeutics Inc.

Akebia to Present at the Credit Suisse 25th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7, 2016 at 1:00 p.m. Mountain Time. The conference will take place at The Phoenician in Scottsdale, Arizona.

A live audio webcast of the presentation will be available on the company's website at http://ir.akebia.com/events.cfm. Archived presentations will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, MA, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia has commenced its vadadustat Phase 3 program, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and INNO2VATE studies for dialysis-dependent patients. For more information, please visit our website at www.akebia.com.

EN
31/10/2016

Underlying

AKBAAkebia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akebia Therapeutics Inc.

 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and ...

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CA...

August 7, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Grow...

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place August 12-14, 2025 in Boston. A webcast of the presentation can be accessed through the “Investors” section of A...

August 6, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunct...

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a week CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL trial, conducte...

August 4, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia’s common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise...

August 1, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Report Second Quarter 2025 Financial Results an...

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights Akebia to Host Conference Call on August 7, 2025, at 8:00 a.m. EDT CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register ...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch